Loading stock data…
Tenax Therapeutics, Inc. (TENX)
$1.98+0.04 (+2.06%)
Market ClosedLast close Sep 8
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tenax Therapeutics, Inc. in the Healthcare sector is trading at $1.98 with a market capitalization of $503M. Wall Street consensus targets $12.56 (9 analysts), implying a +534.1% move over the next 12 months. The stock is currently near its 52-week low of $1.31, remaining 83.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +534.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.78M↓ | -$16.57M↓ | -$16.45M↑ | -$16.81M↓ | -$11.79M |
| Net Income | -$17.80M↓ | -$15.72M↓ | -$15.54M↑ | -$15.80M↓ | -$10.85M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatme...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$502.98M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-57.10%
Volume
Today's trading volume
7.47M
Recent News
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?
Tenax Therapeutics, Inc. (NASDAQ:TENX) has a possible route forward for TNX-103, but the Phase 3 LEVEL trial did not establish efficacy in the overall population. The study evaluated oral levosimendan in 241 patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF. At Week 12, the adjusted improvement in six-minute walk […]
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Tenax Therapeutics’ stock crashes on Phase III trial failure
Despite the miss, a subgroup of patients with more severe disease showed more meaningful benefit - data Tenax plans to submit to the FDA and EMA.
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case
Tenax Therapeutics (NASDAQ:TENX) reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemody
Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103
The pivotal study failed to show a statistically significant improvement in exercise capacity or its key secondary symptom endpoint, although prespecified subgroup and biomarker findings are prompting Tenax to pursue a revised registrational strategy with the FDA. Key Investor TakeawaysTenax Therapeutics (NASDAQ:TENX) said its Phase 3 LEVEL trial of TNX-103 did not meet the primary 6-minute walk distance endpoint or the key secondary KCCQ symptom endpoint.